Back to search
FDAFDA · Food and drugs·Recall number D-1479-2016

Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06

Published September 14, 2016 · Recall initiated: August 23, 2016

Summary

FDA records drug Class III recall D-1479-2016, published September 14, 2016 and initiated August 23, 2016. Recalling firm: Stason Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 17,013 units; Lot: Lot #: 14F030, 14F031, 14F032, Exp. June 2017; 15G022, Exp. July 2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Stason Pharmaceuticals, Inc.
Distributor
North Carolina
Lot
Lot #: 14F030, 14F031, 14F032, Exp. June 2017; 15G022, Exp. July 2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06 recalled?

Yes. FDA published recall D-1479-2016 on September 14, 2016. Reported hazard: Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.

What should I do if I have this product?

Voluntary: Firm initiated · Letter